Please provide your email address to receive an email when new articles are posted on . The Osprey and Apteryx trials will assess QLS-111, a potassium channel modulator, in patients with glaucoma. The ...
Praxis Precision Medicines has received Breakthrough Therapy Designation (BTD) from the FDA for relutrigine, a sodium channel modulator intended for pediatric treatment of SCN2A and SCN8A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback